Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

BACKGROUND AND OBJECTIVE: Zibotentan, a selective endothelin A receptor antagonist, is in development for chronic liver and kidney disease. The pharmacokinetics (PK) of zibotentan were previously investigated in patients with either renal impairment or hepatic impairment, but the impact of both path...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercier, Anne-Kristina, Sunnåker, Mikael, Ueckert, Sebastian, Pawlik, Tadeusz, Henricson, Emilia, Molodetskyi, Oleksandr, Law, Gordon C., Parker, Victoria E. R., Oscarsson, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684621/
https://www.ncbi.nlm.nih.gov/pubmed/37801266
http://dx.doi.org/10.1007/s40262-023-01306-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684621/
https://www.ncbi.nlm.nih.gov/pubmed/37801266
http://dx.doi.org/10.1007/s40262-023-01306-7

Ejemplares similares